Ranbaxy CEO Looks Past U.S. FDA Troubles To Expanded Generics Sales
This article was originally published in PharmAsia News
Ranbaxy Laboratories, which has had problems with U.S. regulators in the past few years, plans to expand its sales in the market, with a specific aim to be first on the market with newly approved generics.
You may also be interested in...
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.